Overall Survival and Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
In a recent JAMA study, researchers endeavored to determine if there were differences in overall survival among ovarian cancer patients treated with neoadjuvant (prior to surgery) chemotherapy. The study involved 39,299 cancer patients treated from 664 cancer programs. 19,562 patients underwent neoadjuvant chemotherapy, of whom the use of this chemotherapy approach increased from 21.7% in 2004 to 2009 to 42.2% in 2010 to 2015. Outcomes revealed greater improvements in short-term mortality and equivalent gains in median overall survival among patients treated in programs that markedly increased the administration of neoadjuvant chemotherapy compared with patients who were infrequently treated with neoadjuvant chemotherapy.
The implications of this study suggest that for many patients with advanced-stage ovarian cancer, neoadjuvant chemotherapy may be an appropriate first-line therapeutic strategy.
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media: